Semaglutide faces renewed legal battles as Novo Nordisk targets compounding pharmacies for trademark infringement and false advertising after FDA shortage removal.
Dani Heba
Advertisement
Dani Heba is a summer associate in Hunton’s New York office.
Articles by Dani Heba
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
Trump Accounts: What doctors need to know
2
26 coding tips to unlock your practice's hidden revenue potential
3
Clinic owner convicted for $52M Medicare fraud; therapy donkeys; CDC warns of serious infection risks tied to cosmetic surgery tourism – Morning Medical Update
4
How to fix health care: Start with primary care, AHA says
5